Jamjoom Pharmaceuticals Factory Company

SASE:4015 Stock Report

Market Cap: ر.س10.5b

Jamjoom Pharmaceuticals Factory Past Earnings Performance

Past criteria checks 6/6

Jamjoom Pharmaceuticals Factory has been growing earnings at an average annual rate of 16.8%, while the Pharmaceuticals industry saw earnings growing at 9.3% annually. Revenues have been growing at an average rate of 12.4% per year. Jamjoom Pharmaceuticals Factory's return on equity is 24.2%, and it has net margins of 27.6%.

Key information

16.8%

Earnings growth rate

-46.8%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate12.4%
Return on equity24.2%
Net Margin27.6%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Jamjoom Pharmaceuticals Factory Company's (TADAWUL:4015) Business Is Yet to Catch Up With Its Share Price

Dec 17
Jamjoom Pharmaceuticals Factory Company's (TADAWUL:4015) Business Is Yet to Catch Up With Its Share Price

Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely

Apr 30
Getting In Cheap On Jamjoom Pharmaceuticals Factory Company (TADAWUL:4015) Is Unlikely

Revenue & Expenses Breakdown

How Jamjoom Pharmaceuticals Factory makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

SASE:4015 Revenue, expenses and earnings (SAR Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 241,26834937332
30 Jun 241,23333238332
31 Mar 241,18531136832
31 Dec 231,10129235233
30 Sep 231,08928035133
30 Jun 231,03424834133
31 Mar 2397421233334
31 Dec 2291717131633
30 Sep 2293019931234
30 Jun 2290321230033
31 Mar 2282218827135
31 Dec 2173617125237
31 Dec 208052072370
31 Dec 197321572480
31 Dec 187011512710

Quality Earnings: 4015 has high quality earnings.

Growing Profit Margin: 4015's current net profit margins (27.6%) are higher than last year (25.7%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 4015's earnings have grown by 16.8% per year over the past 5 years.

Accelerating Growth: 4015's earnings growth over the past year (24.9%) exceeds its 5-year average (16.8% per year).

Earnings vs Industry: 4015 earnings growth over the past year (24.9%) exceeded the Pharmaceuticals industry 7.2%.


Return on Equity

High ROE: 4015's Return on Equity (24.2%) is considered high.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/03 01:07
End of Day Share Price 2025/01/02 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Jamjoom Pharmaceuticals Factory Company is covered by 4 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Madhu AppissaAl Rajhi Capital
null nullJ.P. Morgan
Tarek SleimanJ.P. Morgan